Elucidating the role of the FXR-PTEN-PI3K-AKT-mTOR axis in liver progenitor cell-driven liver regeneration

阐明 FXR-PTEN-PI3K-AKT-mTOR 轴在肝祖细胞驱动的肝再生中的作用

基本信息

  • 批准号:
    10620261
  • 负责人:
  • 金额:
    $ 51.09万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-09-25 至 2025-05-31
  • 项目状态:
    未结题

项目摘要

Chronic liver diseases are among the leading causes of mortality and morbidity in the U.S., with 5.5 million people suffering from these diseases. Currently, liver transplantation is the only definitive treatment for end-stage liver diseases; however, the shortage of donor livers makes this therapy extremely limited. Augmenting innate liver regeneration in advanced liver diseases is an attractive therapeutic alternative. To develop such a therapy, it is crucial to understand the molecular mechanisms of liver regeneration, particularly in the diseased liver. Upon liver injury, hepatocytes proliferate to yield more hepatocytes to restore lost liver mass and maintain liver function. However, when hepatocyte proliferation is compromised, a phenomenon observed in advanced liver diseases, or when massive hepatocyte necrosis occurs, liver progenitor cells (LPCs) are activated and these LPCs expand and are able to differentiate into hepatocytes. A correlation between disease severity and LPC numbers in patients with chronic liver diseases suggests the occurrence of LPC activation in the diseased livers but its poor differentiation into hepatocytes. In addition, LPCs secrete pro-inflammatory, pro-fibrogenic cytokines that can perpetuate inflammation and contribute to subsequent fibrosis. Thus, augmenting innate LPC-driven liver regeneration is expected to have beneficial effects in liver patients by generating more functional hepatocytes and by concomitantly reducing inflammation and fibrosis. Despite this significance, the molecular basis of LPC- driven liver regeneration remains poorly understood. Our long-term goal is to completely delineate the molecular mechanisms underlying LPC-driven liver regeneration. In pursuit of this goal, during the previous grant cycle, we elucidated the crucial role of bone morphogenetic protein (BMP) signaling in LPC-driven liver regeneration; in this renewal grant application, we propose to determine how the nuclear receptor farnesoid X receptor (FXR) regulates LPC-driven liver regeneration. We have established both zebrafish and mouse liver injury models for LPC-driven liver regeneration. Using the zebrafish model, we performed chemical screening and discovered that treatment with a synthetic FXR agonist, GW4064, impaired LPC-driven regeneration. Given the beneficial effects of FXR agonists on hepatic steatosis, fibrosis, and hepatocyte-driven liver regeneration and the multiple clinical trials of the agonists, their negative effect on LPC-driven liver regeneration is unexpected and surprising, justifying an extensive mechanistic investigation. Based on our preliminary findings, we hypothesize that FXR activation impairs LPC-driven liver regeneration by repressing the PI3K-AKT-mTOR pathway. We will test this hypothesis by elucidating the effects of FXR activation and suppression on LPC-driven liver regeneration (Aim 1) and by determining the role of the PTEN-PI3K-AKT-mTOR axis in the regeneration process (Aim 2). Successful accomplishment of the proposed work will not only significantly advance the mechanistic understanding of liver regeneration in diseased livers, but also support a more cautionary administration of FXR agonists for treating patients with advanced liver diseases.
在美国,慢性肝病是导致死亡和发病的主要原因之一,有550万人

项目成果

期刊论文数量(20)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Hepatocyte-to-cholangiocyte conversion occurs through transdifferentiation independently of proliferation in zebrafish.
  • DOI:
    10.1097/hep.0000000000000016
  • 发表时间:
    2023-04-01
  • 期刊:
  • 影响因子:
    13.5
  • 作者:
    Lee, Seung-Hoon;So, Juhoon;Shin, Donghun
  • 通讯作者:
    Shin, Donghun
tomm22 Knockdown-Mediated Hepatocyte Damages Elicit Both the Formation of Hybrid Hepatocytes and Biliary Conversion to Hepatocytes in Zebrafish Larvae.
tomm22 敲低介导的肝细胞损伤引起斑马鱼幼虫中混合肝细胞的形成和胆汁向肝细胞的转化。
  • DOI:
    10.3727/105221617x695195
  • 发表时间:
    2017
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Wu,Jianchen;Choi,Tae-Young;Shin,Donghun
  • 通讯作者:
    Shin,Donghun
PPARα activation promotes liver progenitor cell-mediated liver regeneration by suppressing YAP signaling in zebrafish.
  • DOI:
    10.1038/s41598-023-44935-5
  • 发表时间:
    2023-10-25
  • 期刊:
  • 影响因子:
    4.6
  • 作者:
    Kim, Minwook;So, Juhoon;Shin, Donghun
  • 通讯作者:
    Shin, Donghun
Attenuating the Epidermal Growth Factor Receptor-Extracellular Signal-Regulated Kinase-Sex-Determining Region Y-Box 9 Axis Promotes Liver Progenitor Cell-Mediated Liver Regeneration in Zebrafish.
  • DOI:
    10.1002/hep.31437
  • 发表时间:
    2021-04
  • 期刊:
  • 影响因子:
    0
  • 作者:
    So J;Kim M;Lee SH;Ko S;Lee DA;Park H;Azuma M;Parsons MJ;Prober D;Shin D
  • 通讯作者:
    Shin D
Biliary-Atresia-Associated Mannosidase-1-Alpha-2 Gene Regulates Biliary and Ciliary Morphogenesis and Laterality.
  • DOI:
    10.3389/fphys.2020.538701
  • 发表时间:
    2020
  • 期刊:
  • 影响因子:
    4
  • 作者:
    So J;Ningappa M;Glessner J;Min J;Ashokkumar C;Ranganathan S;Higgs BW;Li D;Sun Q;Schmitt L;Biery AC;Dobrowolski S;Trautz C;Fuhrman L;Schwartz MC;Klena NT;Fusco J;Prasadan K;Adenuga M;Mohamed N;Yan Q;Chen W;Horne W;Dhawan A;Sharif K;Kelly D;Squires RH;Gittes GK;Hakonarson H;Morell V;Lo C;Subramaniam S;Shin D;Sindhi R
  • 通讯作者:
    Sindhi R
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Donghun Shin其他文献

Donghun Shin的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Donghun Shin', 18)}}的其他基金

Delineating the molecular mechanisms of hepatocyte-to-cholangiocyte reprogramming
描述肝细胞到胆​​管细胞重编程的分子机制
  • 批准号:
    10596146
  • 财政年份:
    2022
  • 资助金额:
    $ 51.09万
  • 项目类别:
Delineating the molecular mechanisms of hepatocyte-to-cholangiocyte reprogramming
描述肝细胞到胆​​管细胞重编程的分子机制
  • 批准号:
    10415302
  • 财政年份:
    2022
  • 资助金额:
    $ 51.09万
  • 项目类别:
Elucidating the Mechanisms by which Bmp Signaling Regulates Biliary-Driven Liver Regeneration
阐明 Bmp 信号调节胆道驱动的肝脏再生的机制
  • 批准号:
    9270021
  • 财政年份:
    2014
  • 资助金额:
    $ 51.09万
  • 项目类别:
Elucidating the Mechanisms by which Bmp Signaling Regulates Biliary-Driven Liver Regeneration
阐明 Bmp 信号调节胆道驱动的肝脏再生的机制
  • 批准号:
    8813644
  • 财政年份:
    2014
  • 资助金额:
    $ 51.09万
  • 项目类别:
Elucidating the role of the FXR-PTEN-PI3K-AKT-mTOR axis in liver progenitor cell-driven liver regeneration
阐明 FXR-PTEN-PI3K-AKT-mTOR 轴在肝祖细胞驱动的肝再生中的作用
  • 批准号:
    10402799
  • 财政年份:
    2014
  • 资助金额:
    $ 51.09万
  • 项目类别:
Elucidating the Mechanisms by which Bmp Signaling Regulates Biliary-Driven Liver Regeneration
阐明 Bmp 信号调节胆道驱动的肝脏再生的机制
  • 批准号:
    8931956
  • 财政年份:
    2014
  • 资助金额:
    $ 51.09万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 51.09万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 51.09万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 51.09万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 51.09万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 51.09万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 51.09万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 51.09万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 51.09万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 51.09万
  • 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
  • 批准号:
    23K05057
  • 财政年份:
    2023
  • 资助金额:
    $ 51.09万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了